Moderna has received a grant of $176m through the Rapid Response Partnership Vehicle (RRPV) Consortium to expedite the development of mRNA-based pandemic influenza vaccines.

The RRPV Consortium, funded by the Biomedical Advanced Research and Development Authority (BARDA), operates under the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS).

The funding supports the late-stage development needed to license a pre-pandemic vaccine targeting the H5 influenza virus.

The H5 subtype is known for causing severe avian influenza, with potential risks of spillover to humans.

The project also encompasses other options to enhance preparedness for and response to future public health emergencies.

In 2023, Moderna commenced a Phase I/II clinical trial to assess the safety and immune response of its investigational pandemic influenza vaccine, mRNA-1018, in adults aged 18 years and above.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study evaluates vaccine candidates for both H5 and H7 avian influenza strains.

The trial results are anticipated during 2024 and will be vital in shaping the Phase III development strategy.

Moderna CEO Stéphane Bancel stated: “mRNA vaccine technology offers advantages in efficacy, speed of development and production scalability and reliability in addressing infectious disease outbreaks, as demonstrated during the Covid-19 pandemic.

“We are pleased to continue our collaboration with BARDA to expedite our development efforts for mRNA-based pandemic influenza vaccines and support the global public health community in preparedness against potential outbreaks.”

The funding for this initiative is sourced from federal funds provided by the Department of Health and Human Services, the ASPR and BARDA.

In June 2024 Moderna secured US Food and Drug Administration approval for its mRNA-based respiratory syncytial virus vaccine mRESVIA for adults aged 60 and above.

mRNA vaccine coverage on Pharmaceutical Technology (Or Clinical Trials Arena)  is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.